PRNewsWire
17 Aug 2026, 08:36 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Capricor Therapeutics (CAPR) allegedly modified its statistical analysis plan for clinical data for the drug Deramiocel without securing FDA agreement prior to resubmitting its Biologics License Application. — Failure to align clinical analysis plans with the FDA significantly increases the risk of regulatory rejection or delays for a core product candidate.
-0.80A class action lawsuit has been filed against Capricor Therapeutics alleging violations of the Securities Exchange Act due to false and misleading public statements. — Securities litigation creates legal liabilities and suggests potential management transparency issues, though the outcome of such suits is often uncertain.
-0.40Which stocks this story touches
The company is mentioned as being sued for securities law violations.
Continue reading
6 related stories
Search tags
The company is mentioned as being sued for securities law violations.
The company is facing a class action lawsuit for alleged securities law violations and misleading statements regarding clinical data.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
1h ago
